TrialSignal transduction and targeted therapy2026

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Fei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.